Therapeutics News and Research

RSS

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

Baxter net income increases 15% to $615 million for second quarter 2011

Baxter International Inc. today announced strong financial results for the second quarter of 2011, and raised its financial outlook for full-year 2011.

From Baxter International Inc. 21 Jul 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

21 Jul 2011

Promising compounds for new anti-obesity drugs

Though it generally is known that obesity dramatically increases the risk for type 2 diabetes, the biological mechanisms for that connection still are unclear.

21 Jul 2011

Researchers identify IDOL protein as potential new target for lowering LDL cholesterol

High levels of 'bad' cholesterol (LDL cholesterol) are a risk factor for developing atherosclerotic cardiovascular disease (ASCVD) - a disease of the major arterial blood vessels that is one of the major causes of heart attack and stroke.

21 Jul 2011

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million.

21 Jul 2011

PrioNet Canada awards University of Western Ontario $600,000 to study neurodegenerative disorders

The University of Western Ontario is one of nine universities which will share 2.9 million dollars in research grants announced by PrioNet Canada to study Prion diseases and neurodegenerative disorders including Alzheimer's.

21 Jul 2011

USPTO issues patent for Mirna's tumor suppressor microRNAs

Mirna Therapeutics, Inc. announced today that the United States Patent and Trademark Office has allowed multiple patent claims related to the therapeutic application of several tumor suppressor microRNAs.

21 Jul 2011

SuperGen closes acquisition of Astex

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it has closed the transaction to acquire Astex Therapeutics Limited, a privately held, UK-based biotechnology company developing targeted therapies.

21 Jul 2011

USPTO issues patent for Avila's targeted covalent drugs portfolio

Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that the United States Patent and Trademark Office has issued Patent No. 7,982,036, "4,6-Disubstituted Pyrimidines Useful as Kinase Inhibitors."

21 Jul 2011

Registration now open for Transcatheter Cardiovascular Therapeutics 2011

Registration is now open for TCT 2011(Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation, which will return to San Francisco, California, November 7-11, 2011.

20 Jul 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Preliminary data from Amorfix human diagnostic test for Alzheimer's presented at ICAD

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, presented a paper on Sunday July 17th, 2011 at the International Conference on Alzheimer's disease in Paris, France.

19 Jul 2011

Cell Biosciences is now ProteinSimple

Cell Biosciences, Inc. today announced that it has changed its name to ProteinSimple to clearly reflect the Company's core mission in protein research.

From ProteinSimple 18 Jul 2011

QRxPharma seeks NDA approval for MoxDuo IR

QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.

18 Jul 2011

FDA asks Guided Therapeutics to provide additional information on LuViva PMA

Guided Therapeutics, Inc., developer of a rapid and painless biophotonic testing platform for the early detection of cancer, today announced that, after a series of meetings with the U.S. Food and Drug Administration (FDA), and after reviewing draft responses, the FDA has asked the company to provide additional information in the company's response to one remaining question.

15 Jul 2011

Yervoy, a new melanoma drug approved in Australia

Australia has approved the world’s first drug to prolong the lives of people with advanced melanoma. The drug Yervoy received the nod from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the deadliest form of skin cancer but for whom other treatments have failed.

14 Jul 2011

IMM researcher wins prestigious Early Career Bayer Hemophilia Award

Vanessa Oliveira, researcher at the Instituto de Medicina Molecular in Portugal won a prestigious and competitive Early Career Bayer Hemophilia Award. Oliveira will develop a strategy to reprogramme the immune system of hemophilia patients to avoid immune targeting of the most used clotting therapeutics.

14 Jul 2011

Accelrys releases Discovery Studio software for biotherapeutics research

Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced a new release of the Discovery Studio life sciences modeling and simulation software.

14 Jul 2011

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011